Management of alcohol dependence in patients with liver disease

CNS Drugs

Volumn 27, Issue 4, 2013, Pages 287-299

  Addolorato, Giovanni ^a   Mirijello, Antonio ^a   Leggio, Lorenzo ^a,b   Ferrulli, Anna ^a   Landolfi, Raffaele ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYBUTYRIC ACID; ACAMPROSATE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BACLOFEN; CARBOHYDRATE DEFICIENT TRANSFERRIN; DISULFIRAM; GAMMA GLUTAMYLTRANSFERASE; MU OPIATE RECEPTOR; NALTREXONE; ONDANSETRON; PLACEBO; TOPIRAMATE;

ALCOHOL CONSUMPTION; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ALCOHOL WITHDRAWAL; ALCOHOLICS ANONYMOUS; ALCOHOLISM; AUSTRIA; COGNITIVE THERAPY; DRINKING BEHAVIOR; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG PACKAGING; DRUG RESPONSE; EUROPE; FIRST PASS EFFECT; FOLLOW UP; GENETIC POLYMORPHISM; HEPATITIS C; HUMAN; ITALY; LIVER METABOLISM; LIVER TOXICITY; LIVER TRANSPLANTATION; MEAN CORPUSCULAR VOLUME; META ANALYSIS (TOPIC); MIXED INFECTION; MOTIVATIONAL ENHANCEMENT THERAPY; MULTICENTER STUDY (TOPIC); OPIATE ADDICTION; PATIENT COMPLIANCE; PATIENT COUNSELING; PHARMACOGENETICS; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; UNITED STATES;

ALCOHOL ABSTINENCE; ALCOHOL DETERRENTS; ALCOHOL DRINKING; ALCOHOLISM; DRUG APPROVAL; HUMANS; LIVER DISEASES, ALCOHOLIC; RECURRENCE;

EID: 84878217109     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0043-4     Document Type: Review

References (143)

1. Rehm J. The risks associated with alcohol use and alcoholism. Alcohol Res Health. 2011;34:135-43.
2. World Health Organization global status report on alcohol. Geneva: World Health Organization; 2006.
3. Edwards S, Kenna GA, Swift RM, et al. Current and promising pharmacotherapies, and novel research target areas in the treatment of alcohol dependence: A review. Curr Pharm Des. 2011;17:1323-32.
4. Tilg H, Day CP. Management strategies in alcoholic liver disease. Nat Clin Pract Gastroenterol Hepatol. 2007;4:24-34.
5. Bruha R, Dvorak K, Petrtyl J. Alcoholic liver disease. World J Hepatol. 2012;4:81-90.
6. European Association For The Study Of The Liver. EASL Clinical Practical Guidelines: Management of alcoholic liver disease. J Hepatol. 2012;57:399-420.
7. Pessione F, Ramond MJ, Peters L, et al. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int. 2003;23:45-53.
8. McGinnis JM, Foege WH. Actual causes of death in the United States. JAMA. 1993;270:2207-12.
9. Hupkens CL, Knibbe RA, Drop MJ. Alcohol consumption in the European Community: Uniformity and diversity in drinking patterns. Addiction. 1993;88:1391-404.
10. Kessler RC, Crum RM, Warner LA, et al. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the national comorbidity survey. Arch Gen Psychiatry. 1997;54:313-21.
11. National Institute on Alcohol Abuse and Alcoholism. 2000. Tenth Special Report to the U.S. Congress on Alcohol and Health, Washington, DC: U.S. Department of Health and Human Services.
12. Gianoulakis C. Implications of endogenous opioids and dopamine in alcoholism: Human and basic science studies. Alcohol Alcohol. 1996;1:33-42.
13. Sinha R, O'Malley SS. Craving for alcohol: Findings from the clinic and the laboratory. Alcohol Alcohol. 1999;34:223-30.
14. Swift RM. Drug therapy for alcohol dependence. New Engl J Med. 1999;340:1482-90.
15. Verheul R, Van Den Brink W, Geerlings P. A three-pathway psychological model of craving for alcohol. Alcohol Alcohol. 1999;34:197-222.
16. Addolorato G, Abenavoli L, Leggio L, et al. How many cravings? Pharmacological aspects of craving treatment in alcohol addiction: A review. Neuropsychobiology. 2005;51:59-66.
17. Sobell LC, Maisto SA, Sobell MB, et al. Reliability of alcohol abusers' self-reports of drinking behavior. Behav Res Ther. 1979;17:157-60.
18. Saunders JB, Aasland OG, Babor TF, et al. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on early detection of persons with harmful alcohol consumption. Addiction. 1993;88:791-804.
19. http://pubs.niaaa.nih.gov/publications/Practitioner/CliniciansGuide2005/ guide.pdf.
20. Stubbs MA, Morgan MY. Managing alcohol dependence and alcohol-related liver disease: A problem for the hepatologist, psychiatrist or economist? Clin Med. 2011;11:189-93.
21. Meerkerk GJ, Njoo KH, Bongers MB, et al. Comparing the diagnostic accuracy of carbohydrate deficient transferrin, gamma glutamyltransferase, and mean cell volume in a general practice population. Alcohol Clin Exp Res. 1999;23:1052-9.
22. Cohen JA, Kaplan MM. The SGOT/SGPT ratio-an indicator of alcoholic liver disease. Dig Dis Sci. 1979;24:835-8.
23. Berlakovich GA, Soliman T, Freundorfer E, et al. Pretransplant screening of sobriety with carbohydrate-deficient transferrin in patients suffering from alcoholic cirrhosis. Transpl Int. 2004;17:617-21.
24. Bellentani S, Saccoccio G, Costa G, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut. 1997;41:845-50.
25. Walsh K, Alexander G. Alcoholic liver disease. Postgrad Med J. 2000;76:280-6.
26. Klatskin G, Yesner R. Factors in the treatment of Laennec's cirrhosis; clinical and histological changes observed during a control period of bed-rest, alcohol withdrawal, and a minimal basic diet. J Clin Invest. 1949;28:723-35.
27. Wilfred de Alwis NM, Day CP. Genetics of alcoholic liver disease and non-alcoholic fatty liver disease. Semin Liver Dis. 2007;27:44-54.
28. Lieber CS. The discovery of the microsomal ethanol oxidizing system and its physiologic and pathologic role. Drug Metab Rev. 2004;36:511-29.
29. Hrubec Z, Omenn GS. Evidence of a genetic predisposition to alcoholic cirrhosis and psychosis; twin concordances for alcoholism and its biological endpoints by zygosity among male veterans. Alcohol Clin Exp Res. 1981;9:306-9.
30. Nezi V, Deutsch M, Gazouli M, et al. Polymorphisms of the CD14 Genes are Associated with Susceptibility to Alcoholic Liver Disease in Greek Patients. Alcohol Clin Exp Res. 2012;. doi: 10.1111/j.1530-0277.2012.01925.x.
31. Boujedidi H, Bouchet-Delbos L, Cassard-Doulcier AM, et al. Housekeeping gene variability in the liver of alcoholic patients. Alcohol Clin Exp Res. 2012;36:258-66.
32. Addolorato G, Di Campli C, Simoncini M, et al. Oxygen free radical production in rat liver: Dose-related effect of ethanol on perfusion injury. Dig Dis Sci. 2001;46:1057-66.
33. Addolorato G, Leggio L, Ojetti V, et al. Effects of short-term moderate alcohol administration on oxidative stress and nutritional status in healthy males. Appetite. 2008;50:50-6.
34. Albano E. Alcohol, oxidative stress and free radical damage. Proc Nutr Soc. 2006;65:278-90.
35. Addolorato G, Caputo F, Berrnardi M, et al. The treatment of alcohol abuse and alcoholism: Psychosocial and pharmacological management. Alcologia Eur J Alcohol Stud. 2003;15:95-109.
36. Matching alcoholism treatments to client heterogeneity. Project MATCH post-treatment drinking outcomes. J Stud Alcohol. 1997;58:7-29.
37. Nowinski J, Baker S, Carroll KM. Twelve step facilitation therapy manual: A clinical research guide for therapists treating individuals with alcohol abuse and dependence. Project MATCH monograph series, vol 2. Rockville: NIAAA; 1995.
38. Miller WR, Zweben A, DiClemente CC, et al. Motivational enhancement therapy manual, vol. 2. Rockville: NIAAA; 1994.
39. Kadden R, Carroll KM, Donovan D, et al. Cognitive-behavioral coping skills therapy manual: A clinical research guide for therapists treating individuals with alcohol abuse and dependence, vol. 3. Rockville: NIAAA; 1995.
40. Weiss RD, Kueppenbender KD. Combining psychosocial treatment with pharmacotherapy for alcohol dependence. J Clin Psychopharmacol. 2006;26S1:S37-42.
41. Monti P, Abrams D, Kadden R, et al. Treating alcohol dependence: A coping skills training guide. New York: Guilford Press; 1989.
42. Johnson BA, DiClemente CC, Ait-Daoud N, et al. Brief behavioral compliance enhancement treatment (BBCET) manual. In: Johnson BA, Ruiz P, Galanter M, editors. Handbook of clinical alcoholism treatment. Baltimore: LippincottWilliams &Wilkins; 2003. p. 282-301.
43. Mann K, Hermann D. Individualised treatment in alcohol-dependent patients. Eur Arch Psychiatry Clin Neurosci. 2010;260:S116-20.
44. Morgenstern J, Labouvie E, McCrady BS, et al. Affiliation with alcoholics anonymous after treatment: A study of its therapeutic effects and mechanisms of action. J Consult Clin Psychol. 1997;65:768-77.
45. Humphreys K, Moos RH. Reduced substance-abuse-related health care costs among voluntary participants in alcoholics anonymous. Psychiatr Serv. 1996;47:709-13.
46. Swift R. Emerging approaches to managing alcohol dependence. Am J Health Syst Pharm. 2007;64(5 Suppl 3):S12-22.
47. Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA. 1986;256:1449-55.
48. Carroll KM, Nich C, Ball SA, McCance E, et al. One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: Sustained effects of treatment. Addictions. 2000;95:1335-49.
49. Chick J, Gough K, Falkowski W, et al. Disulfiram treatment of alcoholism. Br J Psychiatry. 1992;161:84-9.
50. Eneanya DI, Bianchine JR, Duran DO, et al. The actions of metabolic fate of disulfiram. Annu Rev Pharmacol Toxicol. 1981;21:575-96.
51. Neuman MG, Monteiro M, Rehm J. Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses. Subst Use Misuse. 2006;41:1395-463.
52. Volpicelli JR, Alterman AI, Hayashida M, et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876-80.
53. O'Malley SS, Jaffe AJ, Chang G, et al. Naltrexone and coping skills therapy for alcohol dependence: A controlled study. Arch Gen Psychiatry. 1992;49:881-7.
54. Krystal JH, Cramer JA, Krol WF, et al. Naltrexone in the treatment of alcohol dependence. NEJM. 2001;345:1734-9.
55. Bouza C, Angeles M, Munoz A, et al. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: A systemic review. Addiction. 2004;99:811-28.
56. Srisurapanont M, Jarusaraisin N. Naltrexone for the treatment of alcoholism: A meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2005;8:1-14.
57. Rosner S, Hackl-Herrwerth A, Leucht S, et al. Opiod antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010;12:CD001867.
58. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial. JAMA. 2006;295:2003-17.
59. Oslin DW, Berrettini W, Kranzler HR, et al. A functional polymorphism of the mu-opiod receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology. 2003;28:1546-52.
60. Anton RF, Oroszi G, O'Malley SS, et al. An evaluation of mu-opiod receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: Results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008;65:135-44.
61. Kranzler HR, Wesson DR, Billot L. Naltrexone depot for treatment of alcohol dependence: A multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res. 2004;28:1051-9.
62. Garbutt JC. Efficacy and tolerability of naltrexone in the management of alcohol dependence. Curr Pharm Des. 2010;16:2091-7.
63. De Witte P, Littleton J, Parot P, et al. Neuroprotective and abstinence-promoting effects of acamprosate: Elucidating the mechanism of action. CNS Drugs. 2005;19:517-37.
64. Paille FM, Guelfi JD, Perkins AC, et al. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol. 1995;30:239-47.
65. Sass H, Soyka M, Mann K, et al. Relapse prevention by acamprosate. Results from a placebo controlled study on alcohol dependence. Arch Gen Psychiatry. 1996;53:673-80.
66. Pelc I, Verbanck P, LeBon O, et al. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo controlled dose finding study. Br J Psychiatry. 1997;171:73-7.
67. Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: Results of a meta-analysis. Alcohol Clin Exp Res. 2004;28:51-63.
68. Mason BJ, Goodman AM, Chabac S, et al. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: The role of patient motivation. J Psychiatr Res. 2006;40:383-93.
69. Chick J, Anton R, Checinski K, et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 2000;35:587-93.
70. Tempesta E, Janiri L, Bignamini A, et al. Acamprosate and relapse prevention in the treatment of alcohol dependence: A placebo-controlled study. Alcohol Alcohol. 2000;35:202-9.
71. Rosner S, Hackl-Herrwerth A, Leucht S, et al. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010;8:CD004332.
72. Colombo G, Agabio R, Diaz G, et al. Gamma-hydroxybutyric acid intake in ethanol-preferring sP and nonpreferring sNP rats. Physiol Behav. 1998;64:197-202.
73. Poldrugo F, Addolorato G. The role of gammahydroxybutyric acid in the treatment of alcoholism: From animal to clinical studies. Alcohol Alcohol. 1999;34:15-24.
74. Andriamampandry C, Taleb O, Viry S, et al. Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator gamma-hydroxibutyrate (GHB). FASEB J. 2003;17:1691-3.
75. Gessa GL, Agabio R, Carai MA, et al. Mechanism of the antialcohol effect of gamma-hydroxybutyric acid. Alcohol. 2000;20:271-6.
76. Snead OC, Morley BJ. Ontogeny of gamma-hydroxybutyric acid: Regional concentration in developing rat, monkey and human brain. Brain Res. 1981;227:579-89.
77. Addolorato G, Caputo F, Capristo E, et al. Gamma-hydroxybutyric acid efficacy, potential abuse, and dependence in the treatment of alcohol addiction. Alcohol. 2000;20:217-22.
78. Gallimberti L, Ferri M, Ferrara SD, et al. Gamma-hydroxybutyric acid in the treatment of alcohol dependence: A double blind study. Alcohol Clin Exp Res. 1992;16:673-6.
79. Addolorato G, Castelli E, Stefanini GF, et al. An open multicentric study evaluating 4 hydroxybutyric acid sodium salt (GHB) in the medium term treatment of 179 alcohol dependent patients. Alcohol Alcohol. 1996;31:341-5.
80. Addolorato G, Cibin M, Capristo E, et al. Maintaining abstinence from alcohol with gamma-hydroxybutyric acid. Lancet. 1998;351:38.
81. Leone MA, Vigna-Taglianti F, Avanzi G, et al. Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses. Cochrane Database Syst Rev. 2010;(2):CD006266. doi: 10.1002/14651858.CD006266.pub2.
82. Addolorato G, Leggio L, Ferrulli A, et al. The therapeutic potential of gamma-hydroxybutyric acid for alcohol dependence: Balancing the risks and benefits. A focus on clinical data. Expert Opin Investig Drugs. 2009;18:675-86.
83. Johnson BA. Recent advances in the development of treatments for alcohol and cocaine dependence: Focus on topiramate and other modulators of GABA or glutamate function. CNS Drugs. 2005;19:873-96.
84. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: A randomized controlled trial. Lancet. 2003;361:1677-85.
85. Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence: A randomized controlled trial. JAMA. 2007;298:1641-51.
86. Johnson BA, Rosenthal N, Capece JA, et al. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med. 2008;168:1188-99.
87. Kenna G, Lomastro T, Schiesl A, et al. Review of topiramate: An antiepileptic for the treatment of alcohol dependence. Curr Drug Abuse Rev. 2009;2:135-42.
88. Davidoff RA. Antispasticity drugs: Mechanism of action. Ann Neurol. 1985;17:107-16.
89. Colombo G, Serra S, Brunetti G, et al. The GABA B receptor agonist baclofen and CGP 44532 prevent acquisition of alcohol drinking behavior in alcohol preferring rats. Alcohol Alcohol. 2002;37:499-503.
90. Colombo G, Serra S, Brunetti G, et al. Suppression by baclofen of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats. Drug Alcohol Depend. 2003;70:105-8.
91. Colombo G, Vacca G, Serra S, et al. Baclofen suppresses motivation to consume alcohol in rats. Psychopharmacol. 2003;167:221-4.
92. Addolorato G, Caputo F, Capristo E, et al. Ability of baclofen in reducing alcohol craving and intake. II. Preliminary clinical evidence. Alcohol Clin Exp Res. 2000;24:67-71.
93. Flannery BA, Garbutt JC, Cody MW, et al. Baclofen for alcohol dependence: A preliminary open-label study. Alcohol Clin Exp Res. 2004;28:1517-23.
94. Addolorato G, Caputo F, Capristo E, et al. Baclofen efficacy in reducing alcohol craving and intake: A preliminary double-blind randomized controlled study. Alcohol Alcohol. 2002;37:504-8.
95. Garbutt JC, Kampov-Polevoy AB, Gallop R, et al. Efficacy and safety of baclofen for alcohol dependence: A randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res. 2010;34:1849-57.
96. Leggio L, Garbutt JC, Addolorato G. Effectiveness and safety of baclofen in the treatment of alcohol dependent patients. CNS Neurol Disord Drug Targets. 2010;9:33-44.
97. Addolorato G, Leggio L. Safety and efficacy of baclofen in the treatment of alcohol-dependent patients. Curr Pharm Des. 2010;16:2113-7.
98. Addolorato G, Leggio L, Ferrulli A, et al. Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: Secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol. 2011;46:312-7.
99. Szumlinski KK, Diab ME, Friedman R, et al. Accumbens neurochemical adaptations produced by binge-like alcohol consumption. Psychopharmacology (Berl). 2007;190:415-31.
100. Kenna GA. Medications acting on the serotonergic system for the treatment of alcohol dependent patients. Curr Pharm Des. 2010;16:2126-35.
101. Sellers EM, Toneatto T, Romach MK, et al. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res. 1994;18:879-85.
102. Johnson BA, Roache JD, Javors MA, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. JAMA. 2000;284:963-71.
103. Johnson BA, Roache JD, Ait-Daoud N, et al. Ondansetron reduces the craving of biologically predisposed alcoholics. Psychopharmacology (Berl). 2002;160:408-13.
104. Johnson BA, Ait-Daoud N, Seneviratne C, et al. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry. 2011;168:265-75.
105. Kenna GA, Zywiak WH, McGeary JE, et al. A within-group design of nontreatment seeking 5-HTTLPR genotyped alcohol-dependent subjects receiving ondansetron and sertraline. Alcohol Clin Exp Res. 2009;33:315-23.
106. Lucey MR, Silverman BL, Illeperuma A, et al. Safety of oncemonthly injectable extended-release naltrexone administered to actively drinking alcoholics. Alcohol Clin Exp Res. 2008;32:498-504.
107. Forns X, Caballería J, Bruguera M, et al. Disulfiram-induced hepatitis. Report of four cases and review of the literature. J Hepatol. 1994;21:853-7.
108. Atkinson RL, Berke LK, Drake CR, et al. Effects of long-term therapy with naltrexone on bodyweight in obesity. Clin Pharm Ther. 1985;384:19-22.
109. Tetrault JM, Tate JP, McGinnis KA, et al. Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone. Alcohol Clin Exp Res. 2012;36:318-24.
110. Mason BJ, Heyser CJ. The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence. Expert Opin Drug Saf. 2010;9:177-88.
111. Delgrange T, Khater J, Capron D, et al. Effect of acute administration of acamprosate on the risk of encephalopathy and on arterial pressure in patients with alcoholic cirrhosis. Gastroenterol Clin Biol. 1992;16:687-91.
112. Langry HD, Gillis JC, Davis R. Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs. 1997;54:752-73.
113. Mozayani A, Carter J, Nix R. Distribution of topiramate in a medical examiner's case. J Anal Toxicol. 1999;23:556-8.
114. Addolorato G, Leggio L, Agabio R, et al. Baclofen: A new drug for the treatment of alcohol dependence. Int J Clin Pract. 2006;60:1003-8.
115. Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: Randomised, double-blind controlled study. Lancet. 2007;370:1915-22.
116. Muzyk AJ, Rivelli SK, Gagliardi JP. Defining the role of baclofen for the treatment of alcohol dependence: A systematic review of the evidence. CNS Drugs. 2012;26:69-78.
117. Leggio L, Kenna GA, Ferrulli A, et al. Preliminary findings on the use of metadoxine for the treatment of alcohol dependence and alcoholic liver disease. Hum Psychopharmacol. 2011;26:554-9.
118. Addolorato G, Ancona C, Capristo E, et al. Metadoxine in the treatment of acute and chronic alcoholism: A review. Int J Immunopathol Pharmacol. 2003;16:207-14.
119. Vonghia L, Leggio L, Ferrulli A, et al. Acute alcohol intoxication. Eur J Intern Med. 2008;19:561-7.
120. Pares X, Moreno A, Peralba JM, et al. Action of metadoxine on isolated human and rat alcohol and aldehyde dehydrogenases. Effect on enzymes in chronic ethanol-fed rats. Methods Find Exp Clin Pharmacol. 1991;13:37-42.
121. Calabrese V, Calderone AS, Ragusa N, et al. Effects of metadoxine on cellular formation of fatty acid ethyl esters in ethanol treated rats. Int J Tiss React. 1995;17:101-8.
122. Corsini G, Gelso E, Giuliano G. Effects of metadoxine on main biohumoral changes induced by chronic alcoholism. Clin Ter. 1992;140:251-7.
123. Vedrova NN, Gnezdilova NIu. Metadoxyl in combined treatment of alcohol damage to the liver. Klin Med (Mosk). 2001;79:56-8.
124. Pellegrini-Giampietro DE, Moroni F, Pistelli A, et al. Pyrrolidone carboxylic acid in acute and chronic alcoholism. Preclinical and clinical studies. Recenti Prog Med. 1989;80:160-4.
125. Sinforiani E, Mauri M, Merlo P. Effects of metadoxine on the early phase of cognitive recovery in abstinent alcoholics. Clin Trials J. 1990;27:103.
126. Caballería J, Parés A, Brú C, et al. Metadoxine accelerates fatty liver recovery in alcoholic patients: Results of a randomized double-blind, placebo control trial. Spanish group for the study of alcoholic fatty liver. J Hepatol. 1998;28:54-60.
127. Mao YM, Zeng MD, Li YM, et al. Capsule metadoxine in the treatment of alcoholic liver disease: A randomized, double-blind, placebo controlled, multicenter study. Zhonghua Gan Zang Bing Za Zhi. 2009;17:213-6.
128. Rizzo A, Breda A, Moretto F, et al. Therapeutic use of metadoxine in chronic alcoholism. Double blind study of patients in a department of general medicine. Clin Ter. 1993;142:243-50.
129. Guerrini I, Gentili C, Nelli G, et al. A follow up study on the efficacy of metadoxine in the treatment of alcohol dependence. Subst Abuse Treat Prev Policy. 2006;1:35.
130. Burra P, Senzolo M, Adam R, et al. Liver transplantation for alcoholic liver disease in Europe: A study from the ELTR (European Liver Transplant Registry). Am J Transpl. 2010;10:138-48.
131. Neuberger J. Public and professional attitudes to transplanting alcoholic patients. Liver Transpl. 2007;13:S65-8.
132. Lucey MR, Weinrieb RM. Alcohol and substance abuse. Semin Liver Dis. 2009;29:66-73.
133. Lim JK, Keeffe EB. Liver transplantation for alcoholic liver disease: Current concepts and length of sobriety. Liver Transpl. 2004;10:S31-8.
134. Björnsson E, Olsson J, Rydell A, et al. Long-term follow-up of patients with alcoholic liver disease after liver transplantation in Sweden: Impact of structured management on recidivism. Scand J Gastroenterol. 2005;40:206-16.
135. Gramenzi A, Gitto S, Caputo F, et al. Liver transplantation for patients with alcoholic liver disease: An open question. Dig Liver Dis. 2011;43:843-9.
136. Wagner CC, Haller DL, Olbrisch ME. Relapse prevention treatment for liver transplant patients. J Clin Psychol Med Settings. 1996;3:387-98.
137. Weinrieb RM, Van Horn DH, McLellan AT, et al. Drinking behavior and motivation for treatment among alcohol-dependent liver transplant candidates. J Addict Dis. 2001;20:105-19.
138. Weinrieb RM, Van Horn DH, Mclellan AT, et al. Alcoholism treatment after liver transplantation: Lessons learned from a clinical trial that failed. Psychosomatics. 2001;42:111-5.
139. Georgiou G, Webb K, Griggs K, et al. First report of a psychosocial intervention for patients with alcohol-related liver disease undergoing liver transplantation. Liver Transpl. 2003;9:772-5.
140. Rm Weinrieb, Van Horn Dh, Lynch Kg, et al. A randomized, controlled study of treatment for alcohol dependence in patients awaiting liver transplantation. Liver Transpl. 2011;17:539-47.
141. Erim Y, Beckmann M, Tagay S, et al. Stabilisation of abstinence by means of psychoeducation for patients with alcoholic liver disease awaiting liver transplantation. Psychosom Med Psychoter. 2006;52:341-57.
142. http://www.fda.gov/ohrms/dockets/ac/02/Briefing/3857b1-01-Lipha.pdf.
143. Leggio L, Ferrulli A, Zambon A, et al. Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection. Addict Behav. 2012;37:561-4.